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Abstract
Biomedical ontologies are emerging as critical tools in genomic and proteomic research, where
complex data in disparate resources need to be integrated. A number of ontologies describe
properties that can be attributed to proteins. For example, protein functions are described by the
Gene Ontology (GO) and human diseases by SNOMED CT or ICD10. There is, however, a gap in
the current set of ontologies – one that describes the protein entities themselves and their
relationships. We have designed the PRotein Ontology (PRO) to facilitate protein annotation and
to guide new experiments. The components of PRO extend from the classification of proteins on
the basis of evolutionary relationships to the representation of the multiple protein forms of a gene
(products generated by genetic variation, alternative splicing, proteolytic cleavage, and other post-
translational modifications). PRO will allow the specification of relationships between PRO, GO
and other ontologies in the OBO Foundry. Here we describe the initial development of PRO,
illustrated using human and mouse proteins involved in the transforming growth factor-beta and
bone morphogenetic protein signaling pathways.
Background
Ontology-based methodologies for data integration pro-
mote precise communication between scientists, enable
information retrieval across multiple resources, and
extend the power of computational approaches to per-
form data exploration, inference and mining [1-3]. The
Open Biomedical Ontologies (OBO) library [4] is an
umbrella for ontologies shared across different biological
and medical domains. There is, however, a gap in the cur-
rent OBO library of ontologies – a protein ontology that
defines proteins, protein classes, and their relationships.
Filling this gap will support machine reasoning over the
shared features of related proteins and will foster the inter-
connection between ontologies that describe protein
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development of the Protein Ontology (PRO) [5] that
describes types of proteins and the relations between
them. PRO will concentrate on (a) an ontology of pro-
teins based on evolutionary relatedness (ontology for pro-
tein evolution) and (b) an ontology of the multiple
protein forms produced from a given gene locus (ontol-
ogy for protein forms).
Biomedical ontologies
Like standardized measures and rules of syntax, ontolo-
gies bring the benefits of synchronization. Thus, for an
ontology to be of maximal value, it is crucial to ensure
that for each domain of inquiry there is community con-
vergence on a single ontology. The Open Biomedical
Ontologies (OBO) provides a resource where biomedical
ontologies are made available in a standard format that
allows systematic updating and versioning on the basis of
community feedback. Currently, there are nearly 60
ontologies distributed through the OBO web site, span-
ning domains from anatomy (e.g., Mouse adult anatomy)
to ethology (Loggerhead nesting), and from gene and
gene product features (Sequence Ontology and Gene
Ontology) to phenotypic qualities knowledge (Disease
Ontology).
The OBO Foundry [6], a consortium formed by a subset
of developers of OBO ontologies, has outlined a set of
principles specifying best practices in ontology develop-
ment that are designed to foster interoperability and
ensure a gradual improvement of quality and formal
rigor. Ontologies in the OBO Foundry are required to be
well-documented, to adopt a common formal language,
and to be developed in a collaborative manner. The fol-
lowing summarizes several candidate OBO Foundry
ontologies that are related to PRO.
Gene Ontology (GO)
The Gene Ontology (GO) is by far the most widely used
ontology in any discipline [7]. It aims to formalize the
expression of information about biological processes,
molecular functions, and cellular components through a
controlled vocabulary structured in three mutually inde-
pendent hierarchies. The GO has been used to annotate
the genes of humans and a variety of model organisms,
and it has facilitated both in-depth understanding of biol-
ogy within a single organism and comparison of biologi-
cal processes across multiple organisms.
Sequence Ontology (SO)
The Sequence Ontology (SO) provides a rich set of terms,
relations, and definitions for genome and chromosome
annotation [8]. A subset of SO terms addresses the conse-
quences of gene mutation on protein products; for exam-
ple, whether the mutation decreases or eliminates protein
activity.
Disease Ontology (DO)
Still a work in progress, DO [9] is designed to be a control-
led medical vocabulary to facilitate the mapping of dis-
eases and associated conditions to medical coding
systems such as the ICD10 [10] and SNOMED CT [11],
and to other vocabularies within the Unified Medical Lan-
guage System (UMLS) [12].
Other protein-related ontologies
The PSI-MOD ontology [13] has a comprehensive collec-
tion of terms for annotations that describe various types
of protein modifications, including cross-links and pre-,
co- and post-translational modifications. PSI-MOD is
partly constructed using RESID [14] terms, a controlled
vocabulary for defining modification features of protein
entries in the UniProt Knowledgebase (UniProtKB) [15].
PSI-MI [16] and the INOH Event Ontology (EO) [17] are
ontologies that describe some of the types of protein inter-
action events. Finally, both the INOH Molecule Role
Ontology [18] and Reactome [19], contain molecular
functional group names, abstract molecule names and
concrete molecule names manually collected from litera-
ture. The structure of each of the other protein-related
resources described above aligns well with PRO.
Two other ontologies have been designed for database
integration or annotation. Protein Ontology (PO) [20]
includes terms and relationships to describe attributes of
individual protein forms (such as physicochemical prop-
erties), while the Proteomics Process Ontology (ProPreO)
[21] enables a detailed description of proteomics experi-
mental processes and data. Neither ontology includes the
protein forms themselves.
Protein Ontology development
The development of PRO will proceed by taking a prag-
matically motivated approach to populating classes, rela-
tions, and annotations. We start with an initial set of types
using existing, complementary, curated protein classifica-
tion resources. Relations between these types are defined
following the methodology of the OBO Relations Ontol-
ogy [22]. Connections to other ontologies are used to for-
mulate annotations of PRO classes. Finally, the results are
subjected to manual validation by experts.
An overview of PRO is provided in Figure 1. For brevity,
we refer to the protein evolution component as ProEvo
and the protein forms component as ProForm.
Protein Evolution component (ProEvo)
The diverse proteins we find today in living organisms can
be grouped into protein families, each member of whichPage 2 of 12
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over time by copying events (speciation or gene duplica-
tion), followed by divergence of the copies from each
other. This expansion of a protein family can be repre-
sented as a bifurcating tree: each bifurcating node repre-
sents the copying of an ancestral sequence. These ancestral
sequences are now extinct, but they are inferred from the
sequences we observe today. Despite the passage of mil-
lions of years of divergence, members of each family still
share recognizable similarities. It is therefore often possi-
ble to infer certain properties of the ancestral protein, such
as function, based on the recognizable similarities of its
modern descendants.
During the process of protein evolution, there are por-
tions of proteins – called domains – that are usually copied
in their entirety, presumably because they represent a
minimal functional unit. A protein comprises one or more
domains, usually with additional sequences connecting
and surrounding them. Note that using our definition of
domain, some domains have never combined as modules
with another domain (at least as observed thus far). Pro-
teins with similar domain architecture (that is, the same
combination of domains in the same order) are said to be
homeomorphic. In the case of single-domain proteins, the
evolutionary history is identical to (or is a subtree of) that
of the domain itself. However, the evolutionary history of
multi-domain proteins is more complex: it can only be
represented by a single tree as far back as the earliest
ancestor that contained the same architecture. Prior to
that, one must look to the histories of the constituent
domains.
The relationship between a protein and each of its constit-
uent domains can be modeled using the has_part relation-
ship already defined in the OBO Relation Ontology. The
relationship is most obvious for multi-domain proteins,
but it also holds for single-domain proteins.
One complication is that domains within a multi-domain
protein can be lost in one or more lineages (e.g., [23,24]).
This means that a has_part relationship to this domain
PRO protein ontology overviewFigure 1
PRO protein ontology overview. The figure shows the current (partial) working model and a subset of the possible con-
nections to other ontologies. Blue text boxes:ProEvo component; lavender text boxes: ProForm component.Page 3 of 12
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child class. Therefore, we will use a lacks relationship type
to describe evolutionary loss in the child lineage [25].
The GO molecular function ontology organizes function
classes from the general (at the top of the hierarchy) to the
specific (at the leaf nodes). In contrast, the hierarchy of
ProEvo classes is based on evolutionary relatedness,
organized from the distantly-related (at the top of the
hierarchy) to the more closely related (at the leaf nodes).
In many cases the functional and evolutionary classes will
overlap. However, consider the case of erythrocyte mem-
brane protein band 4.2 (EPB4.2). This protein is a major
component of the red blood cell membrane skeleton [26]
that was co-opted from an ancestral protein-glutamine
gamma-glutamyltransferase [27], but subsequently lost
the ancestral function [28]. In the GO molecular function
ontology, the appropriate association for EPB4.2 is "con-
stituent of cytoskeleton" (GO:0005200). For PRO, its par-
ent is "protein-glutamine gamma-glutamyltransferase."
The evolutionary relationship between the human and
mouse versions of EPB4.2 and protein-glutamine gamma-
glutamyltransferase is represented schematically in Figure
2. The difference in function is not due to gain or loss of
specific sections of protein (domains), since all four pro-
teins share end-to-end similarity and common domain
architecture. However, two of the residues of the catalytic
triad of protein-glutamine gamma-glutamyltransferase
[29] are changed in EPB4.2 (data not shown).
Populating ProEvo classes: Resources
Several resources exist that group proteins according to
function, sequence or structure-based relatedness. We use
four of these resources to guide the initial construction of
PRO. Together, these resources represent all of the basic
elements of a protein evolutionary ontology outlined
above. They provide the set of classes that are most impor-
tant for one of the primary tasks we wish to accomplish
with the evolution component: reliably using experimen-
tal data from other organisms to understand human
genes. Moreover, each of these four resources has been
curated by expert biologists to ensure quality. For clarity,
in the description of these resources, we refer to the sets of
proteins as "groups" or "families" or "clusters," and the
name given to the set as the "class." The section below lists
each resource according to the evolutionary relationships
for which each approach is most appropriate, from the
most distant to the closest.
Structure-based clusters with remote domain homology: SCOP
SCOP (Structural Classification of Proteins) [30] is
arranged hierarchically into four levels: class, fold, super-
family and family. Homology (common ancestry) can be
asserted for proteins in the same family on the basis of
sequence data alone and for proteins in the same super-
family on the basis of three-dimensional (3D) structure
data. Proteins in different superfamilies in the same fold
group or class have similarities in 3D topology but do not
necessarily have a common ancestor. Therefore, only the
SCOP superfamily and family data are relevant for the
purposes of PRO, with the former defining remote
homology (shared ancestry that diverged in the distant
past) and the latter defining close homology (shared
ancestry that diverged in the more recent past).
Sequence-based clusters with close domain homology: Pfam
Pfam domain families [31] are comparable to SCOP fam-
ilies. However, Pfam contains domain definitions even in
the absence of structure information; thus, Pfam repre-
sents a superset of SCOP families. Accordingly, we will use
Pfam domain families in place of SCOP families to repre-
sent the "close" level of evolutionary relatedness for
domains.
Clusters of homologous proteins: PIRSF
The PIRSF family classification system provides protein
classification from superfamily to subfamily levels in a
network structure to reflect the evolutionary relationship
between sets of whole proteins and between whole pro-
teins and domains [32]. The primary PIRSF classification
unit is the homeomorphic family, whose members are
homologous (evolved from a common ancestor) and home-
omorphic (sharing full-length sequence similarity and a
common domain architecture). Basing classification on
whole proteins allows annotation of family-specific bio-
logical functions, biochemical activities, and sequence
features, while an understanding of the domain architec-
ture of a protein provides insight into its general func-
tional and structural properties as well as into complex
evolutionary mechanisms.
Functionally-diverged subfamilies: PANTHER
A PANTHER subfamily [33] is defined as a monophyletic
group of proteins that have distinct functions as com-
pared to other monophyletic groups in the same protein
family. These functional differences can derive from gain
and loss of additional domains or from changes in the
protein sequence.
Populating ProEvo classes: Mechanism
The initial ProEvo classes will derive from the curated pro-
tein clustering resources described above. How one class
relates to another consequently resolves to how each clus-
ter relates to another, and the problem condenses to a
simple mapping exercise. The relationships between
SCOP clusters and Pfam clusters already exist, as do the
relationships between Pfam, PIRSF, and PANTHER. To
facilitate updates and tracking between these initial
resources and ProEvo classes, we will use both PRO acces-
sions and IDs, similar to the system used by UniProt [15].Page 4 of 12
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incremented number as its accession (e.g.,
PRO:00000001) and a source-database cross-reference
(e.g., PRO:PIRSF000001).
Updating ProEvo classes
Once the initial mapping is done – and the classes and
relationships are verified – the composition of the under-
lying clusters and how they interrelate will not be of con-
sequence to PRO except as a source of additional nodes.
That is, source database changes need not be reflected in
the ontology. Consider the example of the hexokinase
family of proteins, which includes xylulokinase [34]. Sup-
pose the initial population of PRO classes yields xyluloki-
nase is_a hexokinase, and the source database is
subsequently modified such that the original xylulokinase
Schematic representation of the evolutionary relationship between human and mouse versions EPB42 and TGM3Figure 2
Schematic representation of the evolutionary relationship between human and mouse versions EPB42 and 
TGM3. Top panel: protein-glutamine gamma-glutamyltransferase (TGM3) and erythrocyte membrane protein band 4.2 
(EPB42) are descended from a common ancestor with glutamyltransferase activity. Middle panel: All four proteins share a com-
mon domain arrangement. Bottom panel: PRO and GO connections. TGM3 and EBP42 are descended from an ancestral trans-
glutaminase (TGase) represented by the large circle. This protein evolved into the ancestral forms of TGM3 and EPB42, 
represented by the ovals. All descendants of the ancestral TGase comprise the parts indicated by blue boxes. Except where 
indicated, all descendants of the ancestral TGase have transglutaminase activity and are involved in protein modification. How-
ever, the ancestral EPB42 lacks these attributes, and instead acquired new attributes not shared by the ancestral TGM3.Page 5 of 12
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ulokinases. The original relation still holds even though
the xylulokinase family no longer exists, so the PRO xylu-
lokinase class does not get deleted. Instead, a new level –
ketopentose kinase – could be inserted between xyluloki-
nase and hexokinase.
Protein Forms component (ProForm)
A number of different protein forms can be derived from
a single gene. Protein databases typically represent only
one reference sequence for a gene product, and do not
have separate entries for mutations that can give rise to
disease, for different forms that arise through variations in
splicing, or for post-translational modifications. For
example, cleavage of a signal peptide is needed for protein
secretion. Also, specific residues can be covalently modi-
fied with a variety of chemical moieties. Some proteins
engage in cyclic processes that involve, for example, phos-
phorylation and dephosphorylation. These various modi-
fied forms of a given gene product are critical to making
precise annotation. For example, many diseases are not
caused by the "normal" protein, but by a genetic variant.
Also, a protein can activate a process when in its phospho-
rylated form, but inhibit that same process when not.
Such nuances are not possible with the existing ontolo-
gies. Therefore, PRO allows for the definition of sequence
forms arising from genetic, splice, and translational varia-
tion, and from post-translational cleavage and modifica-
tion.
Relationships between protein forms will be simple and
direct and make use of existing relations whenever possi-
ble. We will use OBO's Relations Ontology as a source of
well-defined relationships, adding further relationships
on the basis of need. For example, it is biologically reason-
able to say that the product of a post-translational modi-
fication is modified_from the initial protein. However,
using such a relationship adds complexity to the system
and hinders the possible interconnections with other
ontologies. In fact, modified_from is just a more specific
way of asserting that "new entity created_from old entity"
or "new entity derives_from old entity." The three relations
convey identical ideas, but the latter is already part of the
core set of relations [22]. Note, however, that this existing
relation does not accurately describe the relationship
between two variations of the same gene product, nor
does the is_a relation. Therefore, we use a new relation
variant_of for this situation.
Populating ProForm classes: Resources
Both the richness and the usefulness of an ontology stem
from the diversity and comprehensiveness of its classes.
Accordingly, we intend to capture the diverse forms that a
protein can take. UniProtKB/Swiss-Prot contains informa-
tion on sequence variants due to mutation, alternative
splicing, or protein cleavage, and on post-translational
modification. These data, found within the controlled
vocabulary of FT (feature) lines or free text of CC (com-
ment) lines, have been used to populate the appropriate
classes. Other sources of data from which information can
be computationally extracted include MGI [35] and iPro-
Class [36].
Populating ProForm classes: Mechanism
We have developed a parser to transform information
from the sources indicated above into OBO format nodes
and relationships. The parser captures experimentally ver-
ified biological entities, ignoring those labeled as "by sim-
ilarity," "potential," or "probable." There are three kinds
of entities considered by the parser: isoforms, variants,
and cleavage and modification products. For example,
post-translational modification nodes are automatically
populated from UniProtKB based on the FT field and
from iProClass based on the PIR Feature and Post Transla-
tional Modification fields. Automatically-populated Pro-
Form terms are verified by a curator and edited using
OBO-EDIT. Additional terms are added as necessary after
curator review of the literature.
Connecting to - and between - other ontologies
Several ontologies – notably, GO and DO – are pertinent
to protein annotation in that the goal is to annotate gene
products. However, the current representation of proteins
in databases is not amenable to direct connection of
annotation to the appropriate protein forms themselves.
The development of PRO provides this necessary interme-
diary for connections between these other ontologies. For
example, the logical connection between the process term
X and the disease term Y is the protein form Z.
ProEvo connections
Though it is most logical and accurate to connect the
attributes available from other ontologies to specific terms
in the ProForm component, it is nonetheless useful to
make connections to terms of the ProEvo component as
well. Doing so provides the ability to reason across species
– for example, to apply knowledge obtained from a
mouse model to the human protein in the same class.
Pfam, PIRSF, and PANTHER all associate GO classes
(which include the class terms and definitions) with a
homologous group of proteins or domains. We will use
these associations to provide an initial set of relations
between ProEvo domain and protein classes and GO
classes.
Given the possibility of functional shift within a homolo-
gous group of proteins, we propose that the appropriate
relationship between a ProEvo class and a GO class will be
has_ancestral_property, meaning that all instances of thePage 6 of 12
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otherwise specified (see below), the properties of the
ancestor are inherited by all instances of the class, i.e. by
all descendants of the ancestor. However, a subset of pro-
teins in a larger family might, under the influence of nat-
ural selection, diverge so greatly from their ancestors that
they can be considered to form a class of their own. In
such cases, the new class can lose attributes of its ancestor;
that is, the attributes of the ancestral class are not con-
served in all of its descendant classes, as has happened
with the homologous proteins protein-glutamine
gamma-glutamyltransferase and erythrocyte membrane
protein band 4.2. We can handle such situations by intro-
ducing the relation lacks_ancestral_property to represent
this process. Thus, the ancestral erythrocyte membrane
protein band 4.2 lacks_ancestral_property of involvement
in protein modification, but has_ancestral_property struc-
tural constituent of cytoskeleton.
ProForm connections
To support functional annotation and disease under-
standing, relations are defined between ProForm compo-
nent classes and other appropriate ontologies and
controlled vocabularies (Figure 1). Connection of protein
forms to GO classes using appropriate relations will sup-
port accurate functional annotation. Relations defined
between ProForm classes and the Disease Ontology (DO)
will facilitate disease understanding. The Sequence Ontol-
ogy (SO) will provide a structured controlled vocabulary
to describe the consequences of gene mutations on the
protein sequence. For attributes not yet defined in OBO
Foundry ontologies, well-accepted controlled vocabular-
ies will be adopted.
Using the parser described above, cross-references to other
ontologies or knowledgebases (e.g., HUGO, GO, OMIM,
RESID) were extracted from UniProtKB/Swiss-Prot and
MGI entries and mapped to appropriate ontological/con-
trolled vocabulary terms for selected human and mouse
proteins of known disease phenotypes. GO annotations
with experimental evidence were extracted from iPro-
Class. The results were converted into annotations of rela-
tionships between PRO classes and those from other
ontologies and were subjected to verification and litera-
ture-based curation. An example is given below.
A PRO example
Smad proteins are essential to serine/threonine kinase
receptor signaling pathways regulated by phosphoryla-
tion. Smad2 undergoes phosphorylation at serines 465
and 467 upon activation of the transforming growth fac-
tor-beta (TGF-beta) type I receptor [37] (Figure 3). The
phosphorylations permit association of Smad2 with
Smad4, nuclear translocation of the complex, and regula-
tion of transcription [38]. Therefore, the TGF-beta recep-
tor-phosphorylated form is the active Smad2 form. Other
forms of Smad2 are possible (Figure 4). We have curated
a prototype PRO using Smad proteins from the human
and mouse TGF-beta and bone morphogenetic signaling
pathways [5]. Later versions will be expanded to addi-
tional proteins from these and other pathways.
Figure 5 illustrates the PRO structure for the Smad2 pro-
tein. Smad2 belongs to the "smad protein" family (source:
PIRSF037286) and, more specifically, to the subfamily
"receptor-regulated Smad protein, Smad2/Smad3 type"
(source: PIRSF500455). Smad family proteins contain
MH1 and MH2 domains (source: PF03165 and PF03166,
respectively). The former is found in Smad-related pro-
teins and nuclear factor 1 family proteins, whereas the
MH2 domain is exclusively found in Smad proteins.
Smad2 component of the TGF-beta signaling pathwayFigure 3
Smad2 component of the TGF-beta signaling path-
way. Not all protein forms and pathway branches are indi-
cated. The steps shown are preceded by phosphorylation of 
Smad4, TGF-beta binding to the receptor, and receptor 
phosphorylation. Step 1: Phosphorylation of Smad2 by TGF 
beta receptor I. Step 2: Complex formation of Smad2 and 
Smad4. Step 3: Nuclear import of Smad2:Smad4. Step 4: 
Binding of Smad2:Smad4 complex coactivator to responsive 
element.Page 7 of 12
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including a wild-type canonical protein plus any
described splice and genetic variants. Relationships to
GO, PSI-MOD and UMLS are listed under the correspond-
ing node with the use of controlled vocabulary (informa-
tion currently annotated using UMLS will eventually be
replaced by DO). The terms for has_function,
has_modification, participates_in and located_in are applied
only to the appropriate forms based on experimental ver-
ification.
The active phosphorylated form of Smad2
(PRO:00000013) located_in nucleus, derives from Smad2
sequence 1 (PRO:00000011) (designated by the
derives_from symbol ">" preceding the PRO accession
number), which is located_in cytoplasm. Also, the phos-
phorylated form acquires the function-related terms
"transforming growth factor beta receptor, pathway-spe-
cific cytoplasmic mediator activity," "Smad binding," and
"transcription coactivator activity." Two other forms are
derived from further phosphorylation of the active form,
and represent the product obtained after regulation by
other kinases. Phosphorylation by ERK-1 yields a form
(PRO:00000014) with increased transcription coactivator
activity [39] (there is currently no "modulation" ontology
that provides this type of annotation), while phosphoryla-
tion by CAMK2 yields a form (PRO:00000015) that does
not localize to the nucleus and thus is unable to coactivate
transcription.
Smad2 has one splice form that lacks exon 3
(PRO:00000016). This form still maintains the character-
istic functions of the TGF-beta receptor-activated form of
Smad2, but can now bind directly to DNA (as can the
closely-related Smad3 and other so-called R-Smads), and
its transcription activity is further enhanced [40].
Finally, genetic variants related to disease are listed. Muta-
tions in Smad2 have been found in colorectal carcinoma.
TGF-beta signaling occurring during human colorectal
carcinogenesis involves a shift in TGF-beta function,
reducing the cytokine's anti-proliferative effect, while
increasing actions that promote invasion and metastasis
[41]. In the case of the variant with histidine-445
(PRO:00000019), signaling through the TGF-beta path-
way is disrupted. The protein is expressed but is not phos-
phorylated.
Need for a protein ontology
A protein ontology must fill two distinct needs: 1) a struc-
ture to support formal, computer-based inferences of
shared attributes among homologous proteins; and 2) an
explicit representation of the various forms of a given gene
product.
Need for a protein evolution component
Protein sequence homology (i.e., descent from a common
ancestral sequence) is the most widely used approach for
annotating the putative functions of genes. While homol-
ogy with a protein of known, experimentally character-
ized function is a critical tool for inferring the function of
an uncharacterized protein, these inferences must be
made carefully. Because there are no simple rules that can
be applied consistently for all attributes of all proteins,
homology-based inference methods can lead to errors. In
a study of annotation consistency in the FlyBase, the pri-
mary cause (60%) for errors in GO annotations was deter-
mined to be incorrect homology-based inference [42].
However, all of the homology-based errors that were
detected could be corrected using more rigorous whole-
protein family/subfamily-based rules for functional infer-
ence, such as is done in the protein classification data-
bases PANTHER and PIRSF. An ontology of protein
evolution that explicitly models both whole proteins and
parts of proteins (domains) will support formal, compu-
ter-based inferences of shared attributes among homolo-
gous proteins, and will enable more consistent, accurate
and precise computational annotation. Furthermore, such
an ontology will allow for a richer expression of relation-
ships (including negatives such as "lacks" [25]) than is
possible using conventional protein classification data-
bases. This formalization will ensure rigorous application
of experimental data to understanding protein-coding
genes derived from high-throughput genome, cDNA, EST,
or environmental sequencing projects. In addition, it will
allow the transfer of described function/phenotypes of
proteins from model organisms to human orthologs and
may highlight potential candidates to explain a human
disease (see below).
Need for a protein forms component
Alternative splicing and post-translational modifications
give rise to the multiple products of a single gene, each of
which can have different activities and different expres-
sion patterns. Nonetheless, the annotation information in
most model organism and sequence databases is organ-
ized within a single entry, often without indicating which
possible form is the correct object for annotation. Thus,
annotation is associated with protein X when in fact it is
specific to peptide Y derived from protein X, or to isoform
Xa, or to a phosphorylated form of protein X; disease asso-
ciations are more accurately ascribed to mutant forms of
protein X. These various specific entities are natural com-
ponents of pathway ontologies or databases such as
INOH Event Ontology [17] or Reactome [19] (the latter
does contain the relevant entities, but as accessions only
that are not formed into an ontology structure). As bio-
medical data expand, it will be increasingly important to
explicitly represent these protein forms so attributes are
attached to the appropriate entity. For example, the GOPage 8 of 12
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Smad2 indicate that the protein is a complex-forming
nuclear transcription upregulator involved in the TGF-
beta signaling cascade. While this does indeed describe
the major function of Smad2, the annotation is only accu-
rate for two out of the seven forms shown in Figure 4. The
remaining forms either only partly fit this description or
don't fit it at all.
PRO facilitates understanding of human disease
Mouse models can give valuable insight into human biol-
ogy. As indicated in Figure 5, the human and mouse
Smad2 have many common sequence forms. Alternative
splicing of Smad2 exon 3 gives rise to a second distinct
protein isoform. The phosphorylated short Smad2 iso-
form (PRO:00000018), unlike the full-length phosphor-
ylated Smad2 (PRO:00000013), retains the direct DNA-
binding activity (GO:0003677) common to every other
receptor-regulated Smad (R-Smad; including Smads 1, 3,
5, and 8) [43]. Importantly, PRO shows that this form is
common to mouse and human. Knockout mouse experi-
ments indicate that Smad2 plays an essential role in pat-
terning the embryonic axis and specification of definitive
endoderm [44]. Mice that exclusively express the short
isoform correctly specify the anterior-posterior axis and
definitive endoderm and are viable and fertile, suggesting
that the short form activates all essential target genes
downstream of TGF-beta-related ligands early in develop-
ment [45]. The direct comparison between specific mouse
and human sequence forms facilitated by PRO can guide
scientific inquiry. For example, experiments designed to
elucidate the specific role of each human Smad2 isoform
at different developmental stages are suggested by the
information uncovered in the mouse counterparts. The
activities of specific isoforms derived from variants that
are agents of colorectal carcinomas could also be a factor
to investigate.
Conclusion
PRO is designed to be a formal, well-principled and exten-
sible OBO Foundry ontology for proteins, with a basic set
of well-defined relations to support semantic integration
and machine reasoning. PRO development has begun by
including classes relevant to human and mouse proteins
in UniProtKB/Swiss-Prot and MGI, with a focus on dis-
ease-related proteins, but will be expanded on a system-
by-system basis using pathways covered by the INOH
pathway and Reactome databases. The framework
described here can be adopted by scientists interested in
curating PRO classes from other areas of interest.
The development of PRO is expected to create a cycle of
improvement for both the ontology and the protein
knowledgebases from which the initial information is
extracted. For example, literature-based curation revealed
that two of the modifications noted in the UniProtKB
entry SMAD2_HUMAN occur in a single molecule
(PRO:00000014). Such information can be fed back into
the UniProtKB entry, along with the PRO node. Similar
annotations throughout the database will, in turn, pro-
vide a richer information source for PRO.
PRO will have an impact beyond the knowledge con-
tained therein. For example, essentially all homologous
proteins in families referenced by PRO – irrespective of
source organism – can be annotated using PRO terms,
including the attributes from connected ontologies. In
addition, by providing the means to reference specific
protein forms, PRO will foster a precise interconnection
between several ontologies. Comparison of information
among related organisms and related ontologies is indis-
pensable to human disease research.
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Multiple possible Smad2 formsFigure 4
Multiple possible Smad2 forms. Not all possibilities are 
indicated. The third column indicates the known properties 
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A PRO example using nodes and relationships illustrated by Smad2 proteinFigure 5
A PRO example using nodes and relationships illustrated by Smad2 protein. Not all possibilities are indicated. 
Cross-references to source of information (in curly braces) and description of sequence forms (in parentheses) are given for 
clarity. The symbols preceding each PRO accession are as follows: $: root; >: has_part (for domains) or derives_from (for pro-
teins); <: variant_of.
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